亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06855 亚盛医药

休市中 10-09 16:08:08

28.220

+0.200

+0.71%

最高28.620	最低27.120	成交量216.56万
今开28.000	昨收28.020	日振幅5.35%
总市值105.83亿	流通市值105.83亿	总股本3.75亿
成交额6,014万	换手率0.58%	流通股本3.75亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"亚盛医药","latestPrice":28.22,"timestamp":1791533288003,"preClose":28.02,"halted":0,"volume":2165600,"delay":0,"changeRate":0.007137758743754436,"floatShares":375000000,"shares":375000000,"eps":-3.49,"marketStatus":"休市中","change":0.2,"latestTime":"10-09 16:08:08","open":28,"high":28.62,"low":27.12,"amount":60137630,"amplitude":0.053533,"askPrice":28.22,"askSize":20400,"bidPrice":28.2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.560141,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791768600000},"marketStatusCode":7,"adr":0,"listingDate":1572192000000,"exchange":"SEHK","adjPreClose":28.02,"openAndCloseTimeList":[[1791509400000,1791518400000],[1791522000000,1791532800000]],"volumeRatio":1.4714711531888336,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855","defaultTab":"news","newsList":[{"id":"2674783546","title":"亚盛医药，钢丝上的舞者","url":"https://stock-news.laohu8.com/highlight/detail?id=2674783546","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674783546?lang=zh_cn&edition=full","pubTime":"2026-10-09 12:28","pubTimestamp":1791520080,"startTime":"0","endTime":"0","summary":"亚盛医药的故事，便在这两种时态之间，被无数投资者反复掂量。2026年的盛夏，亚盛医药向美国证监会递交文件，拟发行最高2亿美元美国存托凭证。02武田交易亚盛医药的研发开支主要在奥雷巴替尼（耐立克）和利沙托克拉（利生妥）。2024年6月，亚盛与武田制药就奥雷巴替尼达成海外选择权协议，换回1亿美元首付款，另有7500万美元的股权投资。钢丝上的舞者，最忌的不是走得慢，而是失去平衡。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2026-10-09/doc-iniuqywm7008124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK4139","AAPG","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125361185","title":"亚盛医药9月股份变动月报表，已发行股本增至374,962,086股","url":"https://stock-news.laohu8.com/highlight/detail?id=1125361185","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125361185?lang=zh_cn&edition=full","pubTime":"2026-10-07 16:46","pubTimestamp":1791362817,"startTime":"0","endTime":"0","summary":"亚盛医药于2026年10月7日发布了截至2026年9月30日的股份变动月报表。报告期内，公司法定（注册）股本维持5亿股不变，每股面值为0.0001美元，法定股本总额为5万美元。在已发行股份方面，截至8月底，公司普通股总数为373,616,240股。9月份，公司因Restricted Share Unit计划共增发1,345,846股，无任何回购或注销库存股份，导致已发行股票总数上升至374,962,086股。据月报表披露，截至2026年9月底，公司公共持股比例符合香港联交所对主板上市公司最低公众持股量的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101449563","title":"亚盛医药（06855）主席杨大俊三日内增持3.86万股 耗资约115.71万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101449563","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101449563?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:51","pubTimestamp":1790607117,"startTime":"0","endTime":"0","summary":"亚盛医药2026年9月28日自愿公告披露，公司主席兼执行董事杨大俊博士于2026年9月23日至25日通过场内交易累计认购公司38,630股普通股，成交总金额约为115.71万港元，平均认购价格约29.95港元/股。\\n\\n本次增持后，按照香港法例第571章《证券及期货条例》第XV部的相关规定，杨大俊博士的总持股数量由62,531,624股增至62,570,254股，占公司已发行股本总额的比例由约16.68%增至约16.69%。\\n\\n亚盛医药提醒全体股东及潜在投资者，在买卖公司证券时应保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670725684","title":"亚盛医药：主席兼执行董事杨大俊增持3.86万股 总代价约115.71万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670725684","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670725684?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:50","pubTimestamp":1790607000,"startTime":"0","endTime":"0","summary":"南财智讯9月28日电，亚盛医药（06855.HK）发布自愿公告，公司执行董事兼董事会主席杨大俊博士于2026年9月23日至25日在场内认购合共3.86万股公司普通股，总代价约为115.71万港元，平均价约为每股29.95港元，占公司已发行股本总额约0.01%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885543023.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885543023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","06855","BK4139","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670766255","title":"亚盛医药(06855.HK)获执行董事兼董事会主席杨大俊认购合共3.86万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670766255","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670766255?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:47","pubTimestamp":1790606858,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186513524","title":"亚盛医药（06855）受托人斥资142.8万港元再购5万股用于2022年受限制股份单位计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1186513524","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186513524?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:45","pubTimestamp":1790606730,"startTime":"0","endTime":"0","summary":"2026年9月29日，亚盛医药公告披露，受托人已于2026年9月28日通过场内交易购入公司现有股份5万股，用于履行2022年受限制股份单位计划的归属安排。公司强调，受托人持股将依据信托契据及计划规则进行管理，受托人不得行使相关表决权。截至公告日，除已披露的各次首次及进步授出外，公司未有新增奖励授出计划。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670256826","title":"亚盛医药：受托人购买5万股公司股份以满足受限制股份单位计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2670256826","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670256826?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:44","pubTimestamp":1790606640,"startTime":"0","endTime":"0","summary":"南财智讯9月28日电，亚盛医药（06855.HK）发布自愿公告，2026年9月28日，公司受托人就2022年受限制股份单位计划目的于场内购买合共5万股现有股份，占总股本约0.01%，总代价为142.8万港元，每股平均代价约28.56港元。紧随上述购买后，受托人于场内购买的现有股份总数为271.5万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885536325.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885536325.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","BK1161","BK1574","06855","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670255677","title":"亚盛医药(06855.HK)：受托人就2022年受限制股份单位计划目的购买5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670255677","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670255677?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:36","pubTimestamp":1790606189,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","06855","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139813","title":"亚盛医药盘中涨超6%，受托人购买股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139813","media":"同花顺","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139813?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:48","pubTimestamp":1789955280,"startTime":"0","endTime":"0","summary":"9月21日，亚盛医药(06855.HK)盘中涨超6%，截至9时45分，涨6.02%，报31.34港元/股，成交额4157.29万港元。消息面上，亚盛医药公布，于2026年9月17日，受托人就2022年受限制股份单位计划目的 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260921/c680109576.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260921/c680109576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1574","AAPG","BK1161","BK4139","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668967431","title":"亚盛医药(06855)：受托人就2022年受限制股份单位计划目的购买5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668967431","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668967431?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:01","pubTimestamp":1789650089,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药(06855)发布公告，于2026年9月17日，受托人就2022年受限制股份单位计划目的于场内购买合共5万股现有股份以在归属后满足受限制股份单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1161","BK4139","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141601916","title":"亚盛医药集团(06855)受托人9月17日场内购入5万股用于2022年限制性股份单位计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1141601916","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141601916?lang=zh_cn&edition=full","pubTime":"2026-09-17 20:55","pubTimestamp":1789649752,"startTime":"0","endTime":"0","summary":"2026年9月17日，亚盛医药集团发布自愿公告称，其受托人已于同日通过联交所场内累计购入公司股份共计50,000股，用于满足2022年限制性股份单位计划的归属需求。根据公告，受托人持有的相关股份将按照2022年限制性股份单位计划规则及信托契据条款进行管理，期间不享有表决权。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667690236","title":"亚盛医药与北京大学达成战略合作，共筑血液肿瘤协同创新体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2667690236","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667690236?lang=zh_cn&edition=full","pubTime":"2026-09-15 07:40","pubTimestamp":1789429200,"startTime":"0","endTime":"0","summary":"双方将整合临床资源与创新研发优势，共筑血液肿瘤协同创新体系，加快该领域创新成果的临床转化，为患者带来更多获益。北京大学人民医院作为北大医学体系的重要组成部分和国家医学中心建设单位，在血液肿瘤等重大疾病诊疗与研究领域积淀深厚。亚盛医药一直以来与北京大学有着深厚的合作根基与相互的信任。\" 此次战略合作标志着亚盛医药与北京大学在血液肿瘤领域的协同创新进入新阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5046875_ZH46875_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5046875_ZH46875_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["AAPG","BK4139","06855","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199826020","title":"异动解读｜亚盛医药盘中下跌5.21%，生物科技板块持续走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1199826020","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199826020?lang=zh_cn&edition=full","pubTime":"2026-09-11 11:16","pubTimestamp":1789096570,"startTime":"0","endTime":"0","summary":"9月11日，亚盛医药盘中下跌5.21%，报30.92港元/股，成交额4848.85万港元，股价连续两日走低并逼近52周低点。消息面上，生物科技板块持续承压，行业个股普遍下挫，其中剂泰科技-P跌12.82%，康方生物跌3.37%，信达生物跌2.33%，百济神州跌1.35%。基本面方面，公司此前披露的中期业绩显示，上半年收入3.02亿元人民币，同比增长29%，但净亏损由上年同期的5.91亿元扩大至8.17亿元。此外，公司7月启动的最高2亿美元ATM发售计划亦可能对市场情绪构成一定压制。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"亚盛医药跌势延续，生物科技板块承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185236629","title":"异动解读｜亚盛医药盘中下跌5.09%，报32.44港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185236629","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185236629?lang=zh_cn&edition=full","pubTime":"2026-09-10 13:01","pubTimestamp":1789016510,"startTime":"0","endTime":"0","summary":"9月10日，亚盛医药盘中下跌5.09%，报32.44港元/股，成交额5313.37万港元。亚盛医药所在的生物科技行业整体走弱，个股中，信达生物跌3.0%，康方生物跌1.0%，三生制药跌3.59%，百济神州跌0.48%，云顶新耀跌7.37%。亚盛医药集团是一家主要从事血液系统恶性肿瘤疗法的发现、开发和商业化的投资控股公司，核心产品包括耐立克（奥雷巴替尼）及利沙托克拉等，主要用于治疗慢性髓性白血病、急性髓性白血病等多种血液系统恶性肿瘤。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199680560","title":"亚盛医药公布2026年8月股份变动月报，已发行普通股增至373,616,240股","url":"https://stock-news.laohu8.com/highlight/detail?id=1199680560","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199680560?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:06","pubTimestamp":1788523563,"startTime":"0","endTime":"0","summary":"亚盛医药集团于2026年9月4日发布2026年8月股份变动月报，报告期截至2026年8月31日。公告显示，公司于本月完成了5,000股普通股的新增发行，导致已发行普通股由上月底的373,611,240股增至373,616,240股。根据公告，本月内新增发行的5,000股由首次公开发售前购股权计划行使所致，所获得资金为50港元。本月前已授出的首次公开发售后购股权及受限制股份单位计划的上限维持不变，截至8月末潜在可发行股份数量合计约为18,362,465股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186704917","title":"异动解读｜亚盛医药盘中上涨5.02%，世界慢淋日催化叠加中金维持跑赢行业评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1186704917","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186704917?lang=zh_cn&edition=full","pubTime":"2026-09-03 11:09","pubTimestamp":1788404986,"startTime":"0","endTime":"0","summary":"9月3日，亚盛医药盘中上涨5.02%，报34.3港元，成交额5723.52万港元。利生妥已获《CSCO淋巴瘤诊疗指南》I级推荐，并被纳入全国27省194城84个惠民保项目，目前公司正全力推进国家医保谈判。此外，中金近期维持亚盛医药跑赢行业评级，目标价45港元。基本面方面，公司上半年收入3.02亿元人民币，同比增长29.3%，产品销售收入同比增长32.6%，商业化造血能力持续提升，围绕利生妥已布局GLORA等4项全球注册III期临床试验，全球化进程加速。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚盛医药盘中上涨，利生妥迎慢淋日催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130539874","title":"异动解读｜亚盛医药盘中下跌5.2%，报35.0港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1130539874","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130539874?lang=zh_cn&edition=full","pubTime":"2026-08-28 15:45","pubTimestamp":1787903146,"startTime":"0","endTime":"0","summary":"8月28日，亚盛医药盘中下跌5.2%，报35.0港元/股，成交额1.34亿港元。亚盛医药所在的生物科技行业中，板块整体表现偏弱，个股中，康方生物跌6.03%，信达生物涨0.19%，百济神州跌0.62%，云顶新耀跌6.56%，康希诺生物跌10.57%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169928718","title":"异动解读｜亚盛医药盘中上涨13.18%，中期业绩商业化放量叠加券商首予增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1169928718","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169928718?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:59","pubTimestamp":1787817558,"startTime":"0","endTime":"0","summary":"8月27日，亚盛医药盘中上涨13.18%，报37.26港元，成交额1.66亿港元。消息面上，公司于8月20日公布中期业绩，上半年实现总收入3.02亿元人民币，同比增长29%；产品销售收入2.82亿元，同比增长33%，耐立克与利生妥双引擎驱动商业化持续放量。此外，国泰海通证券首予公司\"增持\"评级，目标价59.09港元，预计全年营收10.15亿元，同比增长约77%。公司近期还聘任CBO及CCO两位高管，加速海外商业化布局，全球注册III期临床同步推进，基本面催化集中释放。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚盛医药盘中上涨，商业化放量叠加券商首予增持","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662076169","title":"中金：维持亚盛医药(06855.HK)跑赢行业评级 目标价45港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662076169","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662076169?lang=zh_cn&edition=full","pubTime":"2026-08-26 10:45","pubTimestamp":1787712337,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660347943","title":"亚盛医药(06855)公布2026年中期业绩：商业化造血能力持续提升，全球化进程加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2660347943","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660347943?lang=zh_cn&edition=full","pubTime":"2026-08-20 07:36","pubTimestamp":1787182583,"startTime":"0","endTime":"0","summary":"智通财经APP了解到，亚盛医药今日公布2026年中期业绩。2026年上半年，公司实现总收入3.02亿元人民币，同比增长29%。在耐立克与利生妥两大商业化产品的双引擎驱动下，公司自我造血能力持续加强。报告期内，公司产品销售收入达到人民币2.82亿元，同比增长33%。截至报告期末，公司总货币资金约19亿元人民币，资金储备充足，为全球研发与商业化拓展提供坚实支撑。亚盛医药正全面快速推进这些全球注册III期临床研究，全球创新将迎来收获期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1574","06855","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":-0.0336},{"period":"1month","weight":-0.1744},{"period":"3month","weight":-0.2239},{"period":"6month","weight":-0.4257},{"period":"1year","weight":-0.6166},{"period":"ytd","weight":-0.4599}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":-0.0421},{"period":"3month","weight":0.0015},{"period":"6month","weight":-0.065},{"period":"1year","weight":-0.095},{"period":"ytd","weight":-0.0554}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"亚盛医药集团是一家主要从事血液系统恶性肿瘤疗法的发现、开发和商业化的投资控股公司。该公司的主要产品包括耐立克（奥雷巴替尼）、Lisaftoclax（APG-2575）、Alrizomadlin（APG-115）、Pelcitoclax（APG-1252）、APG-5918、以及APG-2449。该公司的产品主要用于治疗慢性髓性白血病（CML）、急性髓性白血病（AML）、慢性淋巴细胞白血病（CLL）、急性淋巴细胞白血病（ALL）、骨髓增生异常综合征（MDS）以及多发性骨髓瘤（MM）。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.091562},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.033966},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.093205},{"month":4,"riseRate":0.714286,"avgChangeRate":0.098263},{"month":5,"riseRate":0.428571,"avgChangeRate":0.029409},{"month":6,"riseRate":0.714286,"avgChangeRate":0.240354},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.06344},{"month":8,"riseRate":0.714286,"avgChangeRate":0.0422},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.08283},{"month":10,"riseRate":0.428571,"avgChangeRate":0.022417},{"month":11,"riseRate":0.428571,"avgChangeRate":0.061723},{"month":12,"riseRate":0.571429,"avgChangeRate":0.04635}],"exchange":"SEHK","name":"亚盛医药","nameEN":"ASCENTAGE"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药,06855,亚盛医药股票,亚盛医药股票老虎,亚盛医药股票老虎国际,亚盛医药行情,亚盛医药股票行情,亚盛医药股价,亚盛医药股市,亚盛医药股票价格,亚盛医药股票交易,亚盛医药股票购买,亚盛医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}